Attenuation of mania-like behavior in Na+,K+-ATPase α3 mutant mice by prospective therapies for bipolar disorder: Melatonin and exercise

Neuroscience

Volumn 260, Issue , 2014, Pages 195-204

  Kirshenbaum, G S ^a,b   Burgess, C R ^c   Dery N ^d   Fahnestock, M ^d   Peever, J H ^c   Roder, J C ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Atp1a3; Bipolar disorder; Mania; Melatonin; Voluntary exercise

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRAIN DERIVED NEUROTROPHIC FACTOR; MELATONIN; NA+ K+ ADENOSINE TRIPHOSPHATE ALPHA3; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUNNING; SLEEP TIME; WILD TYPE;

ANALYSIS OF VARIANCE; ANOVA; ATP1A3; BDNF; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; EDTA; EEG; ELECTROENCEPHALOGRAPHIC; ELECTROMYOGRAPHIC; ELEVATED PLUS MAZE; ELISA; EMG; ENU; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPM; ETHYLENEDIAMINETETRAACETIC ACID; LDB; LIGHT-DARK BOX; MANIA; MELATONIN; MYK; MYSHKIN; N-ETHYL-N-NITROSOUREA; NA(+),K(+)-ATPASE Α3; RAPID EYE MOVEMENT; REAL-TIME POLYMERASE CHAIN REACTION; REM; RT-PCR; SEM; STANDARD ERROR OF MEAN; VOLUNTARY EXERCISE;

ANIMALS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; EXERCISE THERAPY; FEMALE; HIPPOCAMPUS; MALE; MELATONIN; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOTOR ACTIVITY; SLEEP; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84892466803     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.12.011     Document Type: Article

References (61)

1. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, D.C. fourth ed.
2. Avgustinovich D.F., Lipina T.V., Bondar N.P., Alekseyenko O.V., Kudryavtseva N.N. Features of the genetically defined anxiety in mice. Behav Genet 2000, 30:101-109.
3. Barbosa I.G., Huguet R.B., Mendonca V.A., Neves F.S., Reis H.J., Bauer M.E., Janka Z., Palotas A., Teixeira A.L. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett 2010, 475:95-98.
4. Bauer M., Grof P., Rasgon N., Bschor T., Glenn T., Whybrow P.C. Temporal relation between sleep and mood in patients with bipolar disorder. Bipolar Disord 2006, 8:160-167.
5. Ben J., Soares F.M., Cechetti F., Vuaden F.C., Bonan C.D., Netto C.A., Wyse A.T. Exercise effects on activities of Na(+), K(+)-ATPase, acetylcholinesterase and adenine nucleotides hydrolysis in ovariectomized rats. Brain Res 2009, 1302:248-255.
6. Bersani G., Garavini A. Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:185-191.
7. Brooks P.L., Peever J.H. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci 2011, 31:7111-7121.
8. Burgess C., Tse G., Gillis L., Peever J. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010, 33:1295-1304.
9. Calabrese J.R., Guelfi J.D., Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007, 9:628-635.
10. Clapcote S.J., Duffy S., Xie G., Kirshenbaum G., Bechard A.R., Rodacker Schack V., Petersen J., Sinai L., Saab B.J., Lerch J.P., Minassian B.A., Ackerley C.A., Sled J.G., Cortez M.A., Henderson J.T., Vilsen B., Roder J.C. Mutation I810N in the alpha3 isoform of Na+, K+-ATPase causes impairments in the sodium pump and hyperexcitability in the CNS. Proc Natl Acad Sci U S A 2009, 106:14085-14090.
11. Colombo C., Benedetti F., Barbini B., Campori E., Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res 1999, 86:267-270.
12. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
13. Croyle M.L., Woo A.L., Lingrel J.B. Extensive random mutagenesis analysis of the Na+/K+-ATPase alpha subunit identifies known and previously unidentified amino acid residues that alter ouabain sensitivity-implications for ouabain binding. FEBS J 1997, 248:488-495.
14. El-Mallakh R.S., Stoddard M., Jortani S.A., El-Masri M.A., Sephton S., Valdes R. Aberrant regulation of endogenous ouabain-like factor in bipolar subjects. Psychiatry Res 2010, 178:116-120.
15. Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-β and memory loss. Future Neurol 2011, 6:627-639.
16. Fernandes B.S., Gama C.S., Cereser K.M., Yatham L.N., Fries G.R., Colpo G., de Lucena D., Kunz M., Gomes F.A., Kapczinski F. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
17. Francis B.M., Yang J., Hajderi E., Brown M.E., Michalski B., McLaurin J., Fahnestock M., Mount H.T. Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. Neuropsychopharmacology 2012, 37:1934-1944.
18. Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 2001, 158:100-106.
19. Gao K., Calabrese J.R. Newer treatment studies for bipolar depression. Bipolar Disord 2005, 7(Suppl. 5):13-23.
20. Goldstein I., Lerer E., Laiba E., Mallet J., Mujaheed M., Laurent C., Rosen H., Ebstein R.P., Lichtstein D. Association between sodium- and potassium-activated adenosine triphosphatase alpha isoforms and bipolar disorders. Biol Psychiatry 2009, 65:985-991.
21. Goldstein I., Levy T., Galili D., Ovadia H., Yirmiya R., Rosen H., Lichtstein D. Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006, 60:491-499.
22. Grider G., El-Mallakh R.S., Huff M.O., Buss T.J., Miller J., Valdes R. Endogenous digoxin-like immunoreactive factor (DLIF) serum concentrations are decreased in manic bipolar patients compared to normal controls. J Affect Disord 1999, 54:261-267.
23. Harvey A.G. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008, 165:820-829.
24. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
25. Huang C.C., Chang Y.H., Lee S.Y., Chen S.L., Chen S.H., Chu C.H., Huang S.Y., Tzeng N.S., Lee I.H., Yeh T.L., Yang Y.K., Lu R.B. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:501-507.
26. Jornada L.K., Moretti M., Valvassori S.S., Ferreira C.L., Padilha P.T., Arent C.O., Fries G.R., Kapczinski F., Quevedo J. Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J Psychiatr Res 2010, 44:506-510.
27. Judd L.L., Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003, 73:123-131.
28. Kennedy S.H., Kutcher S.P., Ralevski E., Brown G.M. Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res 1996, 63:219-222.
29. Kirshenbaum G.S., Clapcote S.J., Duffy S., Burgess C.R., Petersen J., Jarowek K.J., Yucel Y.H., Cortez M.A., Snead O.C., Vilsen B., Peever J.H., Ralph M.R., Roder J.C. Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+, K+-ATPase alpha3 sodium pump. Proc Natl Acad Sci U S A 2011, 108:18144-18149.
30. Kucyi A., Alsuwaidan M.T., Liauw S.S., McIntyre R.S. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. Postgrad Med 2010, 122:107-116.
31. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
32. Lamont E.W., Coutu D.L., Cermakian N., Boivin D.B. Circadian rhythms and clock genes in psychotic disorders. Isr J Psychiatry Relat Sci 2010, 47:27-35.
33. Leibenluft E., Albert P.S., Rosenthal N.E., Wehr T.A. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res 1996, 63:161-168.
34. Lima F.D., Oliveira M.S., Furian A.F., Souza M.A., Rambo L.M., Ribeiro L.R., Silva L.F., Retamoso L.T., Hoffmann M.S., Magni D.V., Pereira L., Fighera M.R., Mello C.F., Royes L.F. Adaptation to oxidative challenge induced by chronic physical exercise prevents Na+, K+-ATPase activity inhibition after traumatic brain injury. Brain Res 2009, 1279:147-155.
35. Lima F.D., Oliveira M.S., Furian A.F., Souza M.A., Rambo L.M., Ribeiro L.R., Silva L.F., Retamoso L.T., Hoffmann M.S., Magni D.V., Pereira L., Fighera M.R., Mello C.F., Royes L.F. Adaptation to oxidative challenge induced by chronic physical exercise prevents Na+, K+-ATPase activity inhibition after traumatic brain injury. Brain Res 2009, 1279:147-155.
36. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003, 10:86-98.
37. Meredith G.E., Callen S., Scheuer D.A. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002, 949:218-227.
38. Murray G., Suto M., Hole R., Hale S., Amari E., Michalak E.E. Self-management strategies used by 'high functioning' individuals with bipolar disorder: from research to clinical practice. Clin Psychol Psychother 2011, 18:95-109.
39. Mynett-Johnson L., Murphy V., McCormack J., Shields D.C., Claffey E., Manley P., McKeon P. Evidence for an allelic association between bipolar disorder and a Na+, K+ adenosine triphosphatase alpha subunit gene (ATP1A3). Biol Psychiatry 1998, 44:47-51.
40. Ng F., Dodd S., Berk M. The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. J Affect Disord 2007, 101:259-262.
41. Nurnberger J.I., Adkins S., Lahiri D.K., Mayeda A., Hu K., Lewy A., Miller A., Bowman E.S., Miller M.J., Rau L., Smiley C., Davis-Singh D. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 2000, 57:572-579.
42. Oner P., Cinar F., Kocak H., Gurdol F. Effect of exogenous melatonin on ethanol-induced changes in Na(+), K(+)- and Ca(2+)-ATPase activities in rat synaptosomes. Neurochem Res 2002, 27:1619-1623.
43. Rose A.M., Mellett B.J., Valdes R., Kleinman J.E., Herman M.M., Li R., el-Mallakh R.S. Alpha 2 isoform of the Na, K-adenosine triphosphatase is reduced in temporal cortex of bipolar individuals. Biol Psychiatry 1998, 44:892-897.
44. Sachs G.S., Nierenberg A.A., Calabrese J.R., Marangell L.B., Wisniewski S.R., Gyulai L., Friedman E.S., Bowden C.L., Fossey M.D., Ostacher M.J., Ketter T.A., Patel J., Hauser P., Rapport D., Martinez J.M., Allen M.H., Miklowitz D.J., Otto M.W., Dennehy E.B., Thase M.E. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356:1711-1722.
45. Sears C., Markie D., Olds R., Fitches A. Evidence of associations between bipolar disorder and the brain-derived neurotrophic factor (BDNF) gene. Bipolar Disord 2012, 13:630-637.
46. Seifuddin F., Mahon P.B., Judy J., Pirooznia M., Jancic D., Taylor J., Goes F.S., Potash J.B., Zandi P.P. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:508-518.
47. Soares J.C., Young A. Bipolar disorders: basic mechanisms and therapeutic implications 2007, Informa Healthcare, New York.
48. Soleimani L., Roder J.C., Dennis J.W., Lipina T. Beta N-acetylglucosaminyltransferase V (Mgat5) deficiency reduces the depression-like phenotype in mice. Genes Brain Behav 2008, 7:334-343.
49. Souery D., Papakostas G.I., Trivedi M.H. Treatment-resistant depression. J Clin Psychiatry 2006, 67(Suppl. 6):16-22.
50. Souza M.A., Oliveira M.S., Furian A.F., Rambo L.M., Ribeiro L.R., Lima F.D., Dalla Corte L.C., Silva L.F., Retamoso L.T., Dalla Corte C.L., Puntel G.O., de Avila D.S., Soares F.A., Fighera M.R., de Mello C.F., Royes L.F. Swimming training prevents pentylenetetrazol-induced inhibition of Na+, K+-ATPase activity, seizures, and oxidative stress. Epilepsia 2009, 50:811-823.
51. Steiner J. A questionnaire study of risk-taking in psychiatric patients. Br J Med Psychol 1972, 45:365-374.
52. Sylvia L.G., Nierenberg A.A., Stange J.P., Peckham A.D., Deckersbach T. Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract 2011, 17:224-232.
53. Tochigi M., Iwamoto K., Bundo M., Sasaki T., Kato N., Kato T. Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neurosci Res 2008, 60:184-191.
54. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., Greaney M.G., Jacobs T.G., David S.R., Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999, 156:702-709.
55. Trivedi M.H., Greer T.L., Church T.S., Carmody T.J., Grannemann B.D., Galper D.I., Dunn A.L., Earnest C.P., Sunderajan P., Henley S.S., Blair S.N. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 2011, 72:677-684.
56. Tsai S.J. Is mania caused by overactivity of central brain-derived neurotrophic factor?. Med Hypotheses 2004, 62:19-22.
57. Turek F.W., Gillette M.U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004, 5:523-532.
58. Vaynman S., Ying Z., Gomez-Pinilla F. Exercise induces BDNF and synapsin I to specific hippocampal subfields. J Neurosci Res 2004, 76:356-362.
59. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009, 14:51-59.
60. Young J.W., Minassian A., Paulus M.P., Geyer M.A., Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 2007, 31:882-896.
61. Zoladz J.A., Pilc A. The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J Physiol Pharmacol 2010, 61:533-541.